Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Rosetta Genomics's share price for the quarter that ended in Jun. 2017 was $2.35. Rosetta Genomics's Shares Outstanding (EOP) for the quarter that ended in Jun. 2017 was 2.59 Mil. Therefore, Rosetta Genomics's market cap for the quarter that ended in Jun. 2017 was $6.08 Mil.
Rosetta Genomics's quarterly market cap
declined
from Sep. 2016 ($17.32 Mil) to Dec. 2016 ($9.29 Mil) and
declined
from Dec. 2016 ($9.29 Mil) to Jun. 2017 ($6.08 Mil).
Rosetta Genomics's annual market cap
declined
from Dec. 2014 ($26.58 Mil) to Dec. 2015 ($25.23 Mil) and
declined
from Dec. 2015 ($25.23 Mil) to Dec. 2016 ($9.29 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Rosetta Genomics's Enterprise Value for Today is $0.00 Mil.
Rosetta Genomics Market Cap Historical Data
The historical data trend for Rosetta Genomics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Rosetta Genomics's Market Cap
For the Diagnostics & Research subindustry, Rosetta Genomics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rosetta Genomics's Market Cap Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Market Cap distribution charts can be found below:
* The bar in red indicates where Rosetta Genomics's Market Cap falls into.
Rosetta Genomics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Rosetta Genomics's Market Cap for the fiscal year that ended in Dec. 2016 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rosetta Genomics (OTCPK:ROSGQ) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Rosetta Genomics Market Cap Related Terms
Thank you for viewing the detailed overview of Rosetta Genomics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Rosetta Genomics (Rosetta Genomics) Business Description
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROSGQ has been successfully added to your 